AstraZeneca PLC (LON:AZN) Given Average Rating of “Moderate Buy” by Analysts

AstraZeneca PLC (LON:AZN) has been given an average rating of “Moderate Buy” by the six analysts that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is GBX 6,303.50 ($83.73).

AZN has been the topic of several research analyst reports. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, February 19th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Tuesday, April 29th. Finally, Berenberg Bank restated a “buy” rating and issued a GBX 140 ($1.86) target price on shares of AstraZeneca in a report on Wednesday, March 26th.

AstraZeneca Stock Up 0.9%

Shares of AZN stock opened at £102.30 ($135.89) on Friday. AstraZeneca has a 1 year low of GBX 9,573.51 ($127.17) and a 1 year high of £133.88 ($177.84). The stock has a market cap of £196.83 billion, a PE ratio of 28.04, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The business’s fifty day moving average is £107.21 and its 200-day moving average is £108.68. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.